Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0352 • ACR Convergence 2024
Fast-tracking Axial Spondyloarthritis Diagnosis: A Novel Approach to Public Health Advocacy and Awareness
Joe Eddison, National Axial Spondyloarthritis Society, London, United Kingdom
Background/Purpose: The Act on Axial SpA campaign is dedicated to minimising the lengthy 8.5-year delay in diagnosing axial spondyloarthritis (axial SpA) by implementing a pioneering…
Abstract Number: 0578 • ACR Convergence 2024
Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Muhammad Saeed¹, HIna Ahmed² and Aziza Ahmed³, and Arthritis Carte Foundation Faculty, ¹Central Park Medical College, Arthritis Care Foundation, Lahore, Pakistan, ²Central Park Medical College, Lahore, Pakistan, ³Rashid Latif Medical College, Lahore, Pakistan
Background/Purpose: In patients with Axial Spondyloarthritis (axSpA) there has been wide variability in terms of gender regarding disease characteristics as well as outcomes across different…
Abstract Number: 1296 • ACR Convergence 2024
Effectiveness of Inflammatory Arthritides Educational Modules and Potential for Improved Referral Times
Christine Kim¹, Vincent Vertalino², Karen Kruzer³ and Allen Anandarajah⁴, ¹University of Rochester, Rochester, ²University of Rochester, Hamburg, NY, ³University of Rochester, Victor, NY, ⁴University of Rochester Medical Center, Rochester, NY
Background/Purpose: Early diagnosis and treatment of inflammatory arthritides [rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)] are associated with improved patient outcomes. However,…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 2346 • ACR Convergence 2024
Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
Pauline KRUG¹, Anthony Lichaa¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive chronic inflammatory disease. In its early stages, symptoms appear without radiographic evidence. Later, structural lesions are observed on…
Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0580 • ACR Convergence 2024
Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis
Ayantika Talukdar¹, Neke Ibeh², Rohan Machhar², Mansi Aparnathi³, Sareh Keshavarazi⁴, Archita Srinath⁵, Akihiro Nakamura⁶, Robert Inman⁷, Proton Rahman⁸, Igor Jurisica⁹ and Nigil Haroon¹⁰, ¹Krembil Research Institute, UHN, Toronto, ON, Canada, ²UHN, Toronto, Canada, ³University Health Network, Toronto, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Queen's Univesity, Kingston, ON, Canada, ⁷University Health Network, Toronto, ON, Canada, ⁸Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁹Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ¹⁰Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
Abstract Number: 1316 • ACR Convergence 2024
Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Bella Garg¹, John Antowan² and daniel Furst³, ¹Centinela Hospital Medical Center, Inglewood, CA, ²UCLA, Los Angeles, ³Pacific Arthritis Center, Inglewood
Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
Abstract Number: 1710 • ACR Convergence 2024
Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA
Stéphane Hilliquin¹, OLIVIER FOGEL², Mathilde Tissier³, Chahrazad Cherifi⁴, Karim Ibrahim⁵, Judith Melki⁶, Robert Olaso⁷, Brigitte Baroukh⁵, Philippe Dieudé⁸, Lars Rogge³, Elisabetta Bianchi³, Marcio Do Cruzeiro⁹, Frederique Cornelis¹⁰, Rik Lories¹⁰, Patricia Albanese⁴, Xavier Houard¹¹, Claire Bardet⁵ and Corinne MICELI¹², ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²AP-HP, Paris, France, ³Institut Pasteur, Université Paris Cité, Immunoregulation Unit, F-75015 Paris, France, PARIS, France, ⁴Laboratoire Gly-CREET, Université Paris-Est Créteil Val de Marne (UPEC) Faculté des sciences et technologies, Créteil, France, ⁵Université Paris Cité, Institut des maladies musculo-squelettiques, Laboratory Orofacial Pathologies, Imaging and Biotherapies URP2496 and FHU-DDS-Net, Dental School, and Plateforme d’Imagerie du Vivant (PIV), Montrouge, France,, Montrouge, France, ⁶Université Paris-Saclay, Laboratory Diseases and Hormones of the Nervous Systems, Inserm U1195, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France, ⁷Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, Evry, Evry, France, ⁸Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ⁹Plateformes PDA et MouseT'IC, Institut Cochin, Université Paris Cité, Paris, France, PARIS, France, ¹⁰Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ¹¹Centre de Recherche Saint-Antoine, UMR_S938 INSERM /Sorbonne Université, Paris, France, Paris, France, ¹²Université de Paris Cité, APHP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) is an inflammatory rheumatic disease characterized, in its axial form, by lesions affecting the spine and/or sacroiliac joints (SIJ). Severe forms of…
Abstract Number: 2352 • ACR Convergence 2024
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Sofia Ramiro¹, Fabian Proft², Raj Sengupta³, Astrid van Tubergen⁴, Anna Molto⁵, Lianne S Gensler⁶, Mitsumasa Kishimoto⁷, Vanessa Taieb⁸, Diana Voiniciuc⁹, Ute Massow¹⁰ and Victoria Navarro Compán¹¹, ¹Leiden University Medical Center, Bunde, Netherlands, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸UCB Pharma, Colombes, France, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim am Rhein, Germany, ¹¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to Week (Wk) 52 in patients (pts) with…
Abstract Number: 0540 • ACR Convergence 2024
Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
Jose Meade Aguilar¹, Jean Liew², Rachael Stovall³, Sofia Ramiro⁴ and Lianne S Gensler⁵, ¹Boston Medical Center, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³University of Washington, Seattle, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…
Abstract Number: 0590 • ACR Convergence 2024
Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
Sofia Ramiro¹, Corine Gaillez², Uta Kiltz³, Lianne S Gensler⁴, Chaitali Pisal⁵, Juergen Braun⁶ and Alexis Ogdie⁷, ¹Leiden University Medical Center, Bunde, Netherlands, ²Novartis Pharma AG, Basel, Switzerland, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Novartis Healthcare Private Limited, Hyderabad, India, ⁶Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
Abstract Number: 1435 • ACR Convergence 2024
Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment
Seong-Hyeok Bak, Kyung-Ann Lee, Eunsun Oh, Hyun-Sook Kim and Seunghyun Kim, Soonchunhyang University Seoul Hospital, seoul, Republic of Korea
Background/Purpose: Axial spondyloarthritis (axSpA) is a group of related inflammatory diseases characterized by enthesitis, synovitis, and osteitis. The assessment of axial enthesitis in the pelvis…
Abstract Number: 1712 • ACR Convergence 2024
Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment
Yulong Tang¹, Jiangnan Xie², Dachun Zhuo¹, Qi ZHU³, Jiucun Wang¹ and Jing Liu², ¹Fudan University, Shanghai, China (People's Republic), ²Fudan University, Shanghai, Shanghai, China (People's Republic), ³Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
Abstract Number: 2363 • ACR Convergence 2024
“How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
Atul Deodhar¹, Elena Nikiphorou², Abhijeet Danve³, Stephen Hall⁴, Vanessa Taieb⁵, Diana Voiniciuc⁶, Marina Magrey⁷ and Xenofon Baraliakos⁸, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²King's College London, London, United Kingdom, ³Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ⁴Cabrini Medical Centre, Monash University, and Emeritus Research, Melbourne, Victoria, Australia, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Slough, United Kingdom, ⁷Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Two phase 3 studies were conducted where treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].